Albumin binding is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-28. Where a claim depends on a specific study, the study is described rather than over-claimed.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
=== Coagulation factor disorders === The best-known coagulation factor disorders are the hemophilias. The three main forms are hemophilia A (factor VIII deficiency), hemophilia B (factor IX deficiency or "Christmas disease") and hemophilia C (factor XI deficiency, mild bleeding tendency). Von Willebrand disease (which behaves more like a platelet disorder except in severe cases), is the most common hereditary bleeding disorder and is characterized as being inherited autosomal recessive or dominant. In this disease, there is a defect in von Willebrand factor (vWF), which mediates the binding of glycoprotein Ib (GPIb) to collagen. This binding helps mediate the activation of platelets and formation of primary hemostasis. In acute or chronic liver failure, there is insufficient production of coagulation factors, possibly increasing risk of bleeding during surgery. Thrombosis is the pathological development of blood clots. These clots may break free and become mobile, forming an embolus or grow to such a size that occludes the vessel in which it developed. An embolism is said to occur when the thrombus (blood clot) becomes a mobile embolus and migrates to another part of the body, interfering with blood circulation and hence impairing organ function downstream of the occlusion. This causes ischemia and often leads to ischemic necrosis of tissue. Most cases of venous thrombosis are due to acquired states (older age, surgery, cancer, immobility).
== Thermodynamics == Self-assembly is an equilibrium process, i.e. the individual and assembled components exist in equilibrium. In addition, the flexibility and the lower free energy conformation is usually a result of a weaker intermolecular force between self-assembled moieties and is essentially enthalpic in nature. The thermodynamics of the self-assembly process can be represented by a simple Gibbs free energy equation:
== Etymology == The term was coined in 1995 from cathelin, due to the characteristic cathelin-like domain present in cathelicidins. The name cathelin itself is coined from cathepsin L inhibitor in 1989.
There has long been a debate over whether newborn infants with cerebral hypoxia should be resuscitated with 100% oxygen or normal air. It has been demonstrated that high concentrations of oxygen lead to generation of oxygen free radicals, which have a role in reperfusion injury after asphyxia. Research by Ola Didrik Saugstad and others led to new international guidelines on newborn resuscitation in 2010, recommending the use of normal air instead of 100% oxygen. Brain damage can occur both during and after oxygen deprivation. During oxygen deprivation, cells die due to an increasing acidity in the brain tissue (acidosis). Additionally, during the period of oxygen deprivation, materials that can easily create free radicals build up. When oxygen enters the tissue these materials interact with oxygen to create high levels of oxidants. Oxidants interfere with the normal brain chemistry and cause further damage (this is known as "reperfusion injury"). Techniques for preventing damage to brain cells are an area of ongoing research. Hypothermia therapy for neonatal encephalopathy is the only evidence-supported therapy, but antioxidant drugs, control of blood glucose levels, and hemodilution (thinning of the blood) coupled with drug-induced hypertension are some treatment techniques currently under investigation. Hyperbaric oxygen therapy is being evaluated with the reduction in total and myocardial creatine phosphokinase levels showing a possible reduction in the overall systemic inflammatory process. In severe cases, it is extremely important to act quickly.
==== 3000–3099 ==== Motor Vehicles (Tests) (Amendment) Regulations 1993 (S.I. 1993/3011) Public Service Vehicles (Conditions of Fitness, Equipment, Use and Certification) (Amendment) Regulations 1993 (S.I. 1993/3012) Goods Vehicles (Plating and Testing) (Amendment) (No. 2) Regulations 1993 (S.I. 1993/3013) Community Customs Code (Consequential Amendment of References) Regulations 1993 (S.I. 1993/3014) Statistics of Trade (Customs and Excise) (Amendment No. 2) Regulations 1993 (S.I. 1993/3015) Retirement Benefits Schemes (Restriction on Discretion to Approve) (Additional Voluntary Contributions) Regulations 1993 (S.I. 1993/3016) Advice and Assistance (Scotland) (Prospective Cost) Revocation Regulations 1993 (S.I. 1993/3017) Inverclyde Royal National Health Service Trust (Establishment) Order 1993 (S.I. 1993/3018) Kirkcaldy Acute Hospitals National Health Service Trust (Establishment) Order 1993 (S.I. 1993/3019) Queen Margaret Hospital National Health Service Trust (Establishment) Order 1993 (S.I. 1993/3020) Stobhill National Health Service Trust (Establishment) Order 1993 (S.I. 1993/3021) Angus National Health Service Trust (Establishment) Order 1993 (S.I. 1993/3022) Glasgow Royal Infirmary University National Health Service Trust (Establishment) Order 1993 (S.I. 1993/3023) Renfrewshire Healthcare National Health Service Trust (Establishment) Order 1993 (S.I. 1993/3024) West Glasgow Hospitals University National Health Service Trust (Establishment) Order 1993 (S.I. 1993/3025) Highland Communities National Health Service Trust (Establishment) Order 1993 (S.I.
Sources: en.wikipedia.org
=== αvβ6-integrin target === The abundance of αvβ6-integrin on most adult human cell types and respective tissues is low. It is however overexpressed in the context of several medical conditions, such as cancer or fibrosis, particularly idiopathic pulmonary fibrosis. In line with the finding that αvβ6-integrin is expressed by epithelial cells, an elevated density of the protein is observed on the cell surfaces of many carcinomas (synonymous to cancers of epithelial origin). Hence, 68Ga-Trivehexin can be used for PET imaging of αvβ6-integrin positive cancers (i.e., those whose cells possess a sufficiently high density of αvβ6 on their surface), including but not limited to pancreatic ductal adenocarcinoma, non-small cell lung cancer, squamous cell carcinomas (SCC) of different origin (most notably, oral and esophageal SCC), as well as breast, ovarian, and bladder cancer. In colorectal cancer, expression of αvβ6-integrin is higher in the more aggressive forms and correlated with reduced overall survival. 68Ga-Trivehexin has a high binding affinity to αvβ6-integrin (IC50 = 0.047 nM). Its affinity to other RGD-binding integrins is much lower (IC50 for αvβ3, αvβ8, and α5β1 are 2.7, 6.2, and 22 nM, respectively; note that for IC50, higher values mean lower affinity), resulting in a high selectivity for αvβ6-integrin.
=== Post mortem or in tissue biopsies === Amyloid beta can be measured semiquantitatively with immunostaining, which also allows one to determine location. Amyloid beta may be primarily vascular, as in cerebral amyloid angiopathy, or in amyloid plaques in white matter. One sensitive method is ELISA which is an immunosorbent assay which utilizes a pair of antibodies that recognize amyloid beta. Atomic force microscopy, which can visualize nanoscale molecular surfaces, can be used to determine the aggregation state of amyloid beta in vitro. Vibrational microspectroscopy is a label-free method that measures the vibration of molecules in tissue samples. Amyloid proteins like Aβ can be detected with this technique because of their high content of β-sheet structures. Dual polarisation interferometry is an optical technique which can measure early stages of aggregation by measuring the molecular size and densities as the fibrils elongate. These aggregate processes can also be studied on lipid bilayer constructs.
The Reconquista was a series of military and cultural campaigns by northern Iberian Christian polities against al-Andalus. The death of the Umayyad emir Abd ar-Rahman II in 852 brought an end to Umayyad efforts to extend authority northward. The discovery in the 830s of a tomb believed to be that of James the Great gave the Christians a powerful patron, and the elevation of Alfonso III of Asturias in the 860s ended a period of uncertain leadership, thereby providing the command required to channel this energy into a wave of expansionism southward. In 868, the region between the Minho and Douro rivers was secured from the Moors by Christian forces under Vímara Peres and constituted as the County of Portugal under him. The first county of Portugal lasted until 1071. In 1096, Alfonso VI of León refounded the county and bestowed it on Henry of Burgundy, who married Alfonso's illegitimate daughter, Teresa of León.
There were some issues with this survey though. The NCVS produces only the annual estimates of victimization. The survey that Christi Guerrini, Jill Robinson, Devan Petersen, and Amy McGuire produced asked the participants about the incidents of victimization over one's lifetime. Their survey also did not restrict other family members to one household. Around 25% of people who responded to the survey said that they have had family members that have been employed by law enforcement which includes security guards and bailiffs. Throughout these surveys, it has been found that there is public support for law enforcement to access genetic genealogy databases.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.